|
Getting your Trinity Audio player ready...
|
In Queensland, a pioneering diagnostic and treatment strategy for bladder cancer is poised to enter a clinical trial, propelled by a startup founded on technology developed by Mater Research and University of Queensland Honorary Professor John Hooper’s innovative approach. The startup secured a substantial AU$ 950,500 CUREator grant from the Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) programme.
Bladder cancer, afflicting approximately 570,000 individuals globally each year, often progresses to an advanced and aggressive stage. Professor Hooper elucidated that their novel technology represents a theranostic advancement, seamlessly integrating diagnostic imaging with precisely targeted therapy.
By enhancing the visibility of cancerous tumour cells on scans, the approach facilitates informed, targeted, and personalised treatments. The technology’s efficacy hinges on its ability to detect a specific protein, potentially revolutionising the diagnosis and treatment of bladder cancer while offering promise for other malignancies such as ovarian, breast, colorectal, prostate, and lung cancer.
The genesis of this transformative technology traces back to Professor Hooper’s extensive research dating back to 2001, culminating in a collaborative effort with the Scripps Research Institute and CSIRO. Noteworthy collaborators include esteemed professionals like Associate Professor Paul Thomas, Associate Professor Matt Roberts, Dr. Niara Oliveira, Dr. Admire Matsika, and Professor Ian Vela from institutions including Royal Brisbane and Women’s Hospital, and Mater Cancer Care Centre. Dr. Roberts emphasised the inadequacies of current scanning and imaging modalities in detecting bladder cancer, underscoring the potential of the protein target to serve as a beacon for precise identification and treatment.
The CUREator scheme, in tandem with its commitment to advancing medical innovation, allocated an additional AU$500,000 to Frontier Inflammasome Therapeutics, bolstering its preclinical endeavours to develop a groundbreaking therapy for inflammatory conditions lacking effective treatments. This venture unfolds within UniQuest’s Queensland Emory Drug Discovery Initiative, in collaboration with Professor Kate Schroder’s Inflammasome Lab at UQ’s Institute for Molecular Bioscience, exemplifying the collaborative spirit driving medical innovation.
UniQuest, the commercialisation arm of the University of Queensland, emerges as a pivotal catalyst in nurturing and propelling both OncoStrike Biopharma and Frontier Inflammasome Therapeutics. The comprehensive support provided by UniQuest underscores its commitment to fostering the translation of cutting-edge research into tangible solutions with significant commercial potential.
One supporter of burgeoning biotechnological endeavours has been instrumental in shepherding 42 clinical and preclinical stage companies through the CUREator ESTAC stream since 2022. Through strategic investment and unwavering support, the supporter continues to spearhead the advancement of promising Australian initiatives, positioning them on a trajectory toward commercial success and societal impact.
Queensland emerges as a beacon of innovation in the realm of medical research and biotechnology, propelled by collaborative efforts between academia, industry, and government initiatives. The convergence of pioneering technologies, visionary leadership, and strategic investment heralds a new era of transformative advancements in healthcare, promising hope and improved outcomes for patients grappling with complex and challenging medical conditions.
The global biotechnology sector, valued at US$1.55 trillion in 2023, is anticipated to experience a robust compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, propelled by technological advancements. Government support, including initiatives aimed at enhancing regulatory frameworks and streamlining approval processes, coupled with improvements in reimbursement policies, fuels market expansion.
The rise of personalised medicine and the proliferation of orphan drug formulations serve as catalysts, fostering innovation and driving the emergence of cutting-edge technology companies within the biotechnology sphere. This convergence of factors not only accelerates the adoption of biotechnological solutions but also creates lucrative opportunities for emerging tech ventures to thrive and contribute to the sector’s growth trajectory.
